跳至主要内容
临床试验/NCT02539472
NCT02539472Unknown不适用

Evaluation of a Combination of Blood Biomarkers for the Early Diagnosis of Mycosis Fungoides

Assistance Publique - Hôpitaux de Paris2 个研究点 分布在 1 个国家目标入组 620 人开始时间: 2015年11月最近更新:
适应症

试验速览

阶段
不适用
入组人数
620
试验地点
2
主要终点
Early MF Benign inflammatory dermatoses

研究概览

简要总结

Mycosis fungoides (MF) is an epidermotropic cutaneous T cell lymphoma characterized by the accumulation of CD4+ T-lymphocytes in the skin. Early MF presents as erythematous patches and/or infiltrated plaques. The diagnosis of early MF is a major diagnostic challenge and the differential diagnosis with inflammatory dermatoses is often very difficult. The histopathological diagnosis is also difficult and delayed. Therefore, it is important to develop biomarkers and/or a combination of biomarkers in order to improve the early diagnostic of MF.

In a previous trial, investigators included 490 patients in a study aiming at identifying skin biomarkers of early MF. Several activating and inhibiting KIRs were found to be interesting for the skin diagnostic of MF, mainly KIR2DL4 and KIR3DL2. Investigators later evaluated blood biomarkers in patients with erythrodermic MF and Sezary Syndrome (SS). This French institutional study demonstrated that the identification by PCR of a combination of 4 blood markers (CD158k/KIR3DL2, PLS3/T-Plastin, Twist and NKp46) allowed a reliable diagnosis of lymphoma in erythrodermic patients. This previously published study interestingly showed that 30% to 50% of patients with early MF expressed at least one of these biomarkers in the blood (unpublished data). Other groups also recently showed that TOX can be a diagnostic tool for MF.

The aim of this study is to establishing an accurate blood diagnosis for early suspected MF by demonstrating that newly identified biomarkers or their combination [5 cutaneous KIR receptor markers (KIR2DS1, KIR2DS3, KIR3DL1, KIR2DL4, KIR3DL2) and 5 blood biomarkers (TOX, Twist-1, PLS3/T-plastin, KIR3DL2, NKp46)] are differentially expressed by patients with MF and patients with inflammatory dermatoses closely resembling MF lesions.

Statistical analysis will establish the best combination of blood biomarkers allowing the differentiation between the two groups of patients, combination that could represent a suitable diagnostic tool for early MF.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with erythematous dermatitis of subacute evolution (> 15 d) or chronic evolution, in the form of patches/plaques, leading to a clinically suspected cutaneous T cell lymphoma
  • Free and informed consent signed
  • Erythematous dermatosis, sub-acute (> 15 days) or chronic, suspicious of MF
  • Lack of previous hemopathy or cutaneous or extra-cutaneous lymphoma
  • Age > 18 years
  • A skin biopsy for routine diagnostic histopathological analysis at the time of inclusion
  • With an analysis of T-cell clonality in blood and skin at the time of inclusion

排除标准

  • Children under 18 years
  • Sick adults under guardianship
  • Patients refusing to participate in the research protocol
  • Subjects not affiliated with the national health insurance system.

结局指标

主要结局

Early MF Benign inflammatory dermatoses

时间窗: 12 months

次要结局

  • Percentage of positivity of each marker(12 months)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验